Description
Lynparza (Olaparib 100 mg/150 mg) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for:
Ovarian Cancer Treatment:
Maintenance Treatment for BRCA-mutated Cancer: This treatment is for adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer with confirmed or suspected BRCA mutations. It is intended for those with a complete or partial response to first-line platinum-based chemotherapy.
Combination Treatment with Bevacizumab: For adults with HRD-positive advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, this treatment combines with bevacizumab for patients responding to first-line platinum-based chemotherapy. A deleterious BRCA mutation or genomic instability defines HRD-positive status.
Treatment for Recurrent BRCA-mutated Cancer: This is aimed at adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with BRCA mutations, who have responded to platinum-based chemotherapy.
Breast Cancer Treatment:
Early Breast Cancer: For adults with HER2-negative, high-risk early breast cancer who have a deleterious or suspected deleterious gBRCA mutation and have received neoadjuvant or adjuvant chemotherapy.
Metastatic Breast Cancer: For adults with HER2-negative metastatic breast cancer who have a deleterious or suspected deleterious gBRCA mutation and have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with HR-positive breast cancer should have previously received endocrine therapy or been deemed unsuitable for it.
Pancreatic Cancer Treatment:
Maintenance treatment for adult patients with harmful or potentially harmful gBRCAm metastatic pancreatic adenocarcinoma, whose disease has remained stable after at least 16 weeks of first-line platinum-based chemotherapy.
Prostate Cancer Treatment:
For adult patients with germline or somatic HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with enzalutamide or abiraterone.
In combination with abiraterone and prednisone or prednisolone for adult patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).
Recommended Dosage: The recommended dosage of Lynparza tablets is 300 mg, taken orally twice a day, with or without food. Patients with metastatic castration-resistant prostate cancer (mCRPC) should also use a gonadotropin-releasing hormone (GnRH) analog concurrently or have undergone a bilateral orchiectomy. For patients with moderate renal impairment (creatinine clearance of 31-50 mL/min), the dosage should be reduced to 200 mg orally twice daily.
If a patient misses a dose of Lynparza, they should take the next dose at the regular scheduled time. Patients should be advised to swallow the tablets whole without chewing, crushing, dissolving, or dividing them.
Reviews
There are no reviews yet.